# US 2018/0021404 A1 · Methods and compositions for treating glaucoma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021404 A1
- Document ID: US20180021404A1
- Status: Published application
- Kind: A1
- Application number: 15/551,205
- Filed: 2016-02-19
- Published: 2018-01-25
- Earliest claimed: 2015-02-20
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Jeffrey L. Goldberg; Travis L. Stiles
- Web page: https://patentgrep.com/patent/US20180021404A1

## CPC

- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- A61K 9/0051: {Ocular inserts or implants}
- A61K 38/185: {Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3}
- A61P 27/06: Antiglaucoma agents or miotics
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 2710/10043: viral genome or elements thereof as genetic vector
- C12N 2710/16643: viral genome or elements thereof as genetic vector
- C12N 2740/15043: viral genome or elements thereof as genetic vector
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided are methods and compositions for treating an ocular disease associated with increased intraocular pressure using a therapeutically effective amount of receptor associated protein (RAP), a derivative of RAP, a variant of RAP, or a fragment of RAP. Also provided are methods and compositions for reducing intraocular pressure.

## Claims

### Claim 1

A method of treating an ocular disease comprising administering to a subject n need thereof a therapeutically effective amount of receptor associated protein (RAP), a derivative of RAP, a variant of RAP, or a fragment of RAP, thereby treating the ocular disease.

### Claim 2 (depends on 1)

The method of claim 1, wherein the ocular disease is glaucoma or intraocular hypertension.

### Claim 3 (depends on 1)

The method of claim 1, wherein administering comprises intravitreal injection.

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The method of claim 1, wherein the subject s human.

### Claim 6 (depends on 1)

The method of claim 1, wherein the administration of RAP, a derivative of RAP, a variant of RAP, or a fragment of RAP results in increased aqueous outflow of the vitreous humor of the eye.

### Claim 7 (depends on 1)

The method of claim 1, wherein the administration comprises intravitreal delivery of a pharmaceutical composition that comprises a delivery vehicle and an expression vector that encodes the RAP, derivative of RAP, variant of RAP, or fragment of RAP.

### Claim 8 (depends on 7)

The method of claim 7, wherein the expression vector is selected from the group consisting of an adenovirus vector, an adeno-associated virus vector, a herpes simplex virus-based vector, a lentivirus vector, and a plasmid vector.

### Claim 9

A method of treating glaucoma comprising administering to a subject in need thereof a therapeutically effective amount of receptor associated protein (RAP), a derivative of RAP, a variant of RAP, or a fragment of RAP, thereby treating glaucoma.

### Claim 10 (depends on 9)

The method of claim 9, wherein administering comprises intravitreal injection.

### Claim 11

(canceled)

### Claim 12 (depends on 9)

The method of claim 9, wherein the subject is human.

### Claim 13 (depends on 9)

The method of claim 9, wherein the administration comprises intravitreal delivery of a pharmaceutical composition that comprises a delivery vehicle and an expression vector that encodes the RAP, derivative of RAP, variant of RAP, or fragment of RAP.

### Claim 14 (depends on 13)

The method of claim 13, wherein the expression vector is selected from the group consisting of an adenovirus vector, an adeno-associated virus vector, a herpes simplex virus-based vector, a lentivirus vector, and a plasmid vector.

### Claim 15 (depends on 9)

The method of claim 9, wherein the administration of RAP, a derivative of RAP, a variant of RAP, or a fragment of RAP results in increased aqueous outflow of the vitreous humor of the eve.

### Claim 16

A method of reducing intraocular pressure in an eye of a subject comprising administering a RAP-conjugated agent, a RAP derivative-conjugated agent, a RAP variant-conjugated agent, or a RAP fragment-conjugated agent.

### Claim 17 (depends on 16)

The method of claim 16, wherein the agent is a neurotrophic or neuroprotective agent.

### Claim 18 (depends on 17)

The method of claim 17, wherein the neurotrophic or neuroprotective agent is selected from the group consisting of brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), neurotrophin-3/4 (NT-3/4), and ciliary neurotrophic factor (CNTF).

### Claim 19 (depends on 16)

The method of claim 16, wherein administering comprises intravitreal injection.

### Claim 20

(canceled)

### Claim 21 (depends on 16)

The method of claim 16, wherein the subject is human.

### Claim 22 (depends on 16)

The method of claim 16, wherein the administration comprises intravitreal delivery vector that encodes the RAP-conjugated agent, the RAP derivative-conjugated agent, the RAP variant-conjugated agent, or the RAP fragment-conjugated agent.

### Claim 23 (depends on 22)

The method of claim 22, wherein the expression vector is selected from the group consisting of an adenovirus vector, an adeno-associated virus vector, a herpes simplex virus-based vector, a lentivirus vector, and a plasmid vector.

### Claim 24 (depends on 16)

The method of claim 16, wherein the administration of the RAP-conjugated agent, RAP derivative-conjugated agent, RAP variant-conjugated agent, or RAP fragment-conjugated agent results in increased aqueous outflow of the vitreous humor of the eye.
